Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Cost of Revenue (2021 - 2024)

Macrogenics (MGNX) has disclosed Cost of Revenue for 4 consecutive years, with $233000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cost of Revenue rose 42.94% to $233000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $233000.0, a 70.01% decrease, with the full-year FY2024 number at $847000.0, up 36.83% from a year prior.
  • Cost of Revenue was $233000.0 for Q4 2024 at Macrogenics, up from $168000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $3.0 million in Q3 2022 to a low of $17000.0 in Q1 2021.
  • A 4-year average of $466750.0 and a median of $172000.0 in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: soared 718.18% in 2022, then crashed 97.17% in 2023.
  • Macrogenics' Cost of Revenue stood at $947000.0 in 2021, then plummeted by 87.75% to $116000.0 in 2022, then soared by 40.52% to $163000.0 in 2023, then surged by 42.94% to $233000.0 in 2024.
  • Per Business Quant, the three most recent readings for MGNX's Cost of Revenue are $233000.0 (Q4 2024), $168000.0 (Q3 2024), and $176000.0 (Q2 2024).